

LifeSci Biotechnology Clinical Trials Index

11/11/2020

Effective at the market close on Friday November 13, 2020, <u>MYOK</u> will be removed from the <u>LifeSci Biotechnology Clinical Trials Index</u> and its value will be redistributed to the remaining index components based on their weights.

• On October 5, 2020, MyoKardia, Inc. agreed to be acquired by Bristol Myers Squibb for \$225.00 per share in cash.